希普利珠单抗(Siplizumab) - 药物靶点：CD2_在研适应症：1型糖尿病，镰状细胞血症，原发性硬化性胆管炎_专利_临床

概要

基本信息

药物类型

单克隆抗体

别名

Siplizumab (USAN/INN)、MEDI-507、TCD 601

+ [2]

靶点

CD2

作用机制

CD2抑制剂(T细胞表面抗原CD2抑制剂)

治疗领域

免疫系统疾病内分泌与代谢疾病遗传病与畸形+ [7]

在研适应症

1型糖尿病镰状细胞血症原发性硬化性胆管炎+ [7]

非在研适应症

急性移植物抗宿主病肾移植急性排斥反应CD22阳性淋巴瘤+ [8]

原研机构

Facultés Universitaires Catholiques de Mons

在研机构

Itbmed AB初创企业

非在研机构

MedImmune LLC

Facultés Universitaires Catholiques de Mons

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评孤儿药 (美国)、孤儿药 (欧盟)

序列信息

Sequence Code 13769128L

Sequence Code 15248634H

关联

31

项与希普利珠单抗相关的临床试验

NCT06326476 / Not yet recruiting早期临床1期IIT

An Open-label Parallel Group Pilot Study to Demonstrate the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis Suppurativa

This study is to investigate the efficacy of siplizumab in the treatment of Hidradenitis Suppurativa.

开始日期2025-01-01

申办/合作机构

The University of Alabama at Birmingham

[+1]

NCT06455280 / Not yet recruiting临床1期IIT

A 12-Month, Open-Label Study Evaluating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Siplizumab as Induction Therapy in Patients With Autoimmune Liver Diseases Undergoing Liver Transplantation (SET-SAIL)

There is a significant unmet need for safe and effective therapeutic approaches to prevent immune-mediated graft injury and its complications in liver transplant (LT) recipients with autoimmune liver disease (AILD) including autoimmune hepatitis and primary sclerosing cholangitis. Siplizumab is an anti-CD2 monoclonal antibody that has demonstrated a favorable safety profile of siplizumab in over 779 human subjects and has been shown to target memory T cells-a key driver in the immune processes surrounding rejection and autoimmunity post LT in AILD. The purpose of this pilot, open-label phase 1 study is to determine the safety of siplizumab for induction in patients with AILD undergoing LT.
Up to eight (8) subjects will receive siplizumab 0.6 mg/kg/dose on the day of transplant (Day 0) and Day 4 post-transplant, for a total of two doses.
All subjects will be followed in the study for 12 months post-LT.

开始日期2024-06-01

申办/合作机构

Columbia University

[+1]

CTIS2023-506174-12-00 / Not yet recruiting

- TCD601H101

开始日期2024-04-16

申办/合作机构-

100 项与希普利珠单抗相关的临床结果

登录后查看更多信息

100 项与希普利珠单抗相关的转化医学

登录后查看更多信息

100 项与希普利珠单抗相关的专利（医药）

登录后查看更多信息

22

项与希普利珠单抗相关的文献（医药）

2023-10-01·American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Siplizumab combination therapy with belatacept or abatacept broadly inhibits human T cell alloreactivity in vitro.

Article

作者: Razavi, Ronia ; Berglund, Erik ; Cvetkovski, Filip ; Berglund, David ; Sellberg, Felix

Combined antigen-specific T cell receptor stimulation and costimulation are needed for complete T cell activation. Belatacept and abatacept are nondepleting fusion proteins blocking CD28/B7 costimulation, whereas siplizumab is a depleting antiCD2 immunoglobulin G1 monoclonal antibody targeting CD2/CD58 costimulation. Herein, the effect of siplizumab combination therapy with abatacept or belatacept on T cell alloreactivity in mixed lymphocyte reactions was investigated. In contrast to monotherapy, the combination of siplizumab with belatacept or abatacept induced near-complete suppression of T cell proliferation and increased the potency of siplizumab-mediated T cell inhibition. Furthermore, dual targeting of CD2 and CD28 costimulation enhanced the selective depletion of memory T cells compared with monotherapy. Although siplizumab monotherapy leads to significant regulatory T cell enrichment, high doses of cytotoxic T-lymphocyte-associated antigen 4 and a human IgG1 Fc fragment in the combination therapy reduced this effect. These results support the clinical evaluation of dual costimulation blockade, combining siplizumab with abatacept or belatacept, for the prophylaxis of organ transplant rejection and improvement of long-term outcomes following transplantation. Ongoing investigative research will elucidate when other forms of siplizumab-based dual costimulatory blockade may be able to induce similarly strong inhibition of T cell activation although still allowing for enrichment of regulatory T cells.

2020-01-01·Scandinavian journal of immunology4区 · 医学

Pharmacokinetic and pharmacodynamic study of a clinically effective anti‐CD2 monoclonal antibody

4区 · 医学

Article

作者: Berglund, David ; Sykes, Megan ; Berglund, Erik ; Griesemer, Adam ; Binder, Christian ; Sachs, David H. ; Fontenot, Jane ; Hope, James ; Sellberg, Felix

Abstract:

The humanized IgG1κ monoclonal antibody siplizumab and its rat parent monoclonal IgG2b antibody BTI‐322 are directed against the CD2 antigen. Siplizumab is species‐specific, reacting with human and chimpanzee cells but not with cells from any other species, including other non‐human primates. Because siplizumab treatment has recently shown great potential in clinical transplantation, we now present the results of our previous pharmacokinetic, pharmacodynamic and safety studies of both antibodies. Fourteen chimpanzees received 1‐3 doses of 0.143 to 5.0 mg/kg iv The effects were followed with flow cytometry on peripheral lymphocytes and staining of lymph nodes. Side effects were recorded. Serum antibody concentrations were followed. Across the doses, a rapid, transient depletion of CD2, CD3, CD4 and CD8 lymphocytes and NK cells was observed for both antibodies. Immune reconstitution was more rapid for BTI‐322 compared to siplizumab. Paracortical lymph node T cell depletion was moderate, estimated at 45% with doses of >0.6 mg/kg. Restoration of lymph node architecture was seen after two weeks to two months for all animals. All four subjects receiving BTI‐322 experienced AEs on the first dosing day, while the eight subjects dosed with siplizumab experienced few mild, transient AEs. Infusion with siplizumab and BTI‐322 resulted in rapid depletion of CD2+ cells in circulation and tissue. Siplizumab had a longer t1/2 and fewer AEs compared to BTI‐322.

2020-01-01·American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons1区 · 医学

Siplizumab selectively depletes effector memory T cells and promotes a relative expansion of alloreactive regulatory T cells in vitro

1区 · 医学

Article

作者: Obradovic, Aleksandar ; Shonts, Brittany ; Berglund, David ; Binder, Christian ; Sellberg, Felix ; Waffarn, Elizabeth ; DeWolf, Susan ; Ho, Siu-Hong ; Danzl, Nichole ; Podestà, Manuel A ; Sykes, Megan

Siplizumab, a humanized anti-CD2 monoclonal antibody, has been used in conditioning regimens for hematopoietic cell transplantation and tolerance induction with combined kidney-bone marrow transplantation. Siplizumab-based tolerance induction regimens deplete T cells globally while enriching regulatory T cells (Tregs) early posttransplantation. Siplizumab inhibits allogeneic mixed-lymphocyte reactions (MLRs) in vitro. We compared the impact of siplizumab on Tregs versus other T cell subsets in HLA-mismatched allogeneic MLRs using PBMCs. Siplizumab predominantly reduced the percentage of CD4⁺ and CD8⁺ effector memory T cells, which express higher CD2 levels than naïve T cells or resting Tregs. Conversely, siplizumab enriched proliferating CD45RA^- FoxP3^HI cells in MLRs. FoxP3 expression was stable over time in siplizumab-containing cultures, consistent with enrichment for bona fide Tregs. Consistently, high-throughput TCRβ CDR3 sequencing of sorted unstimulated and proliferating T cells in MLRs revealed selective expansion of donor-reactive Tregs along with depletion of donor-reactive CD4⁺ effector/memory T cells in siplizumab-containing MLRs. These results indicate that siplizumab may have immunomodulatory functions that may contribute to its success in tolerance-inducing regimens. Our studies also confirm that naïve in addition to effector/memory T cells contribute to the allogeneic MLR and mandate further investigation of the impact of siplizumab on alloreactive naïve T cells.

2

项与希普利珠单抗相关的新闻（医药）

2023-09-14

·Pharmaceutical Technology

FDA accepts Madrigal’s liver disease therapy NDA for review

Resmetirom will target crucial underlying causes of NASH in the liver. Credit: crystal light / Shutterstock.com. The US Food and Drug Administration (FDA) has accepted for review Madrigal Pharmaceuticals ’s new drug application (NDA) for resmeritom, a liver disease therapy. Resmetirom is indicated for treating adult patients with nonalcoholic steatohepatitis (NASH) with liver fibrosis. Recommended Reports Reports LOA and PTSR Model - Siplizumab in Liver Transplant Rejection GlobalData Reports LOA and PTSR Model - Aldafermin in Liver Cirrhosis GlobalData View all Companies Intelligence Madrigal Pharmaceuticals Inc Nash S.r.L. View all The regulator has granted priority review and set a Prescription Drug User Fee Act date of 14 March 2024. Resmetirom is a once-daily, oral, thyroid hormone receptor (THR)-β selective agonist that targets crucial underlying causes of NASH in the liver. Its clinical development programme consists of 18 clinical studies: 12 trials in Phase I, two in Phase II and four in Phase III. The company is seeking approval to treat patients with NASH and liver fibrosis under the FDA’s accelerated approval pathway. Madrigal CEO Bill Sibold stated: “NASH with liver fibrosis represents a significant unmet need in healthcare today: the disease has a serious impact on patients and, without treatment, it can lead to increased risk of cirrhosis, liver failure, liver cancer and premature mortality. “Resmetirom is a liver-directed therapy that has demonstrated the potential to treat the liver fibrosis that is associated with these negative outcomes, while resolving the underlying steatohepatitis that drives the disease.” NASH, which is a major cause of mortality related to the liver, is an advanced form of nonalcoholic fatty liver disease.

优先审批临床2期申请上市临床3期

2023-08-14

·Pharmaceutical Technology

vTv announces Phase III plans for type 1 diabetes drug cadisegliatin

Phalguni Deswal @Phalguni_GD Image Credit: Shutterstock/antoniodiaz vTv Therapeutics plans to initiate a Phase III clinical trial for cadisegliatin for treating type 1 diabetes (T1D) by the end of 2023 before filing for marketing approval with the US Food and Drug Administration (FDA). Cadisegliatin is a liver-selective glucokinase activator that is used as an adjunct therapy with insulin. It received a breakthrough therapy designation (BTD) based on its Phase II trial (NCT03335371) , which showed a 40% decrease in the frequency of severe and symptomatic hypoglycaemic events along with a decrease in serum and urine ketone events in the treatment group. Recommended Reports Reports LOA and PTSR Model - Siplizumab in Type 1 Diabetes (Juvenile Diabetes) GlobalData Reports LOA and PTSR Model - Golimumab in Type 1 Diabetes (Juvenile Diabetes) GlobalData View all Companies Intelligence vTv Therapeutics Inc Cantex Pharmaceuticals Inc VTV View all The Phase III trial will assess the reduction in the number of hypoglycaemic events with cadisegliatin, compared to placebo. This primary endpoint for the trial is recommended by the FDA as part of the approval data for T1D drugs. vTv plans to expand the drug indications for cadisegliatin to potentially include type 2 diabetes, chronic obstructive pulmonary disease, renal disease, primary mitochondrial myopathy, glioblastoma and other cancer, and related conditions. Hypoglycaemia is a significant concern for patients with T1D, as insulin treatment causes hypoglycaemia in these patients. Other drugs currently in development for treating insulin-induced hypoglycaemia include Zucara Therapeutics’ ZT-01 . vTv’s other drug azeliragon is currently in Phase II/III of development for triple-negative breast cancer by its partner, Cantex Pharmaceuticals. Azeliragon is a receptor for advanced glycation end products (RAGE) inhibitor which is being investigated for multiple indications including Alzheimer’s disease , Covid-19 complications, brain metastasis, glioblastoma, inflammatory lung disease, and other cancer indications. The company’s cash reserves stand at $12.6m as of 30 June 2023. vTv now has until 18 December 2023 to comply with Nasdaq’s Minimum Bid Requirement, which requires a company’s ordinary shares to have a value of at least $1 for a minimum of ten business days. The value of vTv’s share stands at $0.72, as of the market close on 11 August, with a market cap of $58.75m.

临床2期突破性疗法临床3期临床结果

100 项与希普利珠单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D05847	希普利珠单抗	-	DB06371

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
镰状细胞血症	临床2期	美国	Itbmed AB初创企业	2023-09-28
1型糖尿病	临床2期	比利时	Itbmed AB初创企业	2023-01-23
1型糖尿病	临床2期	法国	Itbmed AB初创企业	2023-01-23
1型糖尿病	临床2期	德国	Itbmed AB初创企业	2023-01-23
1型糖尿病	临床2期	意大利	Itbmed AB初创企业	2023-01-23
1型糖尿病	临床2期	波兰	Itbmed AB初创企业	2023-01-23
1型糖尿病	临床2期	西班牙	Itbmed AB初创企业	2023-01-23
1型糖尿病	临床2期	瑞典	Itbmed AB初创企业	2023-01-23
1型糖尿病	临床2期	英国	Itbmed AB初创企业	2023-01-23
斑块状银屑病	临床2期	美国	MedImmune LLC	2001-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01780454 (CTgov)	临床1/2期	终末期肾脏病	2	Thymic Irradiation+MEDI-507+Rituximab	窪餘積繭鏇艱衊願積餘(醖選醖簾範窪蓋艱選蓋) = 鬱遞鏇衊衊襯鑰憲壓窪襯壓蓋鏇鬱廠鑰鹹築艱 (築願齋糧鏇範蓋積範鏇, 網餘蓋糧廠範網淵蓋壓 ~ 艱醖艱艱窪窪蓋鑰選鏇) 更多	-	2020-09-23
Pubmed	临床1期	外周T细胞淋巴瘤	-	Siplizumab	獵選淵鬱醖廠鑰選繭蓋(廠壓構襯繭顧鹹蓋積醖) = 簾壓築淵選遞醖積鏇選淵簾膚襯蓋憲鏇壓淵鑰 (顧糧艱鬱淵築夢壓衊顧 )	-	2018-06-03
NCT00801632 (CTgov)	临床2期	终末期肾脏病	5	rituximab+MEDI-507+methylprednisolone+Cyclophosphamide+Prednisone+tacrolimus+steroid	製顧積製鹹獵憲製夢廠(蓋夢壓鏇襯壓鏇憲糧齋) = 憲齋淵觸糧窪顧艱廠醖觸製觸齋獵範鏇衊襯構 (鹽窪獵構鑰鬱鏇糧製鑰, 淵簾簾衊衊夢淵網鹹顧 ~ 觸鹽簾衊製餘選鏇廠鏇) 更多	-	2015-05-12
ASCO2005	临床1期	淋巴组织增生性疾病	9	Siplizumab	蓋繭廠鬱觸夢築築窪製(憲襯糧網襯構簾鑰衊鏇) = 積鏇構鹽築鹹簾網築鏇壓觸願齋艱繭夢襯網範 (蓋顧網範鑰選鹹鹽糧壓, 24–99) 更多	-	2005-06-01